PROTACs Enter Commercial Licensing; Gilead Closes $5B Tubulis; Lilly Makes Its 7th Acquisition of 2026

The week of May 17–24, 2026 reinforced four themes now defining 2026's deal cycle: (i) ADCs remained the single most-transacted modality, with Gilead's $5B Tubulis acquisition officially closing on May 21; (ii) PROteolysis TArgeting Chimeras (PROTACs) officially entered the commercial licensing era with the Veppanu (vepdegestrant) rights transfer from Arvinas/Pfizer to Rigel Pharmaceuticals — the first deal structured around an FDA-approved PROTAC; (iii) genetic medicine continued its M&A build-out with Lilly's seventh acquisition of 2026 targeting a non-viral DNA delivery platform; and (iv) China-to-West partnering at scale remained the dominant licensing story, with BMS–Hengrui's $15.2B, 13-program collaboration — the second-largest such pact since 2025 — still topping the agenda.

Upfront-to-total deal value remains structurally compressed. The BMS–Hengrui upfront of $600M is roughly 4% of the headline $15.2B biobuck figure — a ratio that will define expectations for comparable multi-program China-to-West licensing conversations in 2026. BD professionals on both sides of the table should anchor negotiations to near-term cash (upfront + first-year payment) rather than headline biobucks, where milestone achievability is the key variable. For licensors, this week validates that multi-asset portfolio licensing can command upfronts exceeding $500M, provided the program count and clinical stage mix is right.

May 17, 2026 — World's First DNA-Guided CRISPR System Breaks RNA-Guidance Paradigm

A research team from the University of Florida reported in Nature Biotechnology the development of the world's first DNA-guided CRISPR editing system, breaking the long-standing paradigm of RNA-guided gene editing. The new system reduces off-target effects by multiple orders of magnitude, cuts production costs by approximately 60%, and triples stability under room-temperature storage — simultaneously addressing three of gene editing's most persistent clinical-translation barriers.

BD Implication: A ~60% cost reduction and room-temperature stability directly attack the two biggest barriers to gene therapy out-licensing — manufacturing economics and cold-chain logistics. Platforms solving these constraints will attract premium licensing terms as gene therapy M&A continues to accelerate.

May 20, 2026 — SCARF2 Identified as Intracellular HBV Receptor Mediating Nuclear Transport

Researchers at the National Institute of Biological Sciences, Beijing published findings in Cell identifying SCARF2 as an intracellular receptor functioning post-viral endocytosis. Acting downstream of NTCP (the established HBV cell-membrane receptor), SCARF2 mediates trafficking of the hepatitis B virus toward the nuclear pore complex and facilitates release of viral nucleocapsids from endosomal vesicles — resolving a core mechanistic gap in HBV biology and unveiling a previously unknown directional transport pathway.

BD Implication: SCARF2 is a newly validated, undrugged target in the ~257M chronic HBV patient population where curative therapies remain elusive. Novel entry points like this will draw early-stage partnership interest from Gilead, Arrowhead, and Roche/Genentech — all of which run active HBV discovery BD mandates.

May 21, 2026 — DRT4 Enzyme Integrates DNA Polymerase and RNA Cleavage in a Single Antiviral Scaffold

A joint research group from Huazhong University of Science and Technology and Wuhan University published in Science demonstrating that a single DRT4 protein integrates DNA polymerase, exonuclease, and endoribonuclease activities to execute RNA-targeted phage defense. The findings reveal a multi-functional immune scaffold combining nucleic acid synthesis and degradation in one enzyme, broadening the functional spectrum of DRT enzymes and establishing a conceptual basis for novel DNA and RNA processing tools.

BD Implication: Earliest-stage science, but platforms combining synthesis and degradation within a single scaffold have direct relevance to next-generation nucleic acid therapeutics (ASO, siRNA, mRNA processing). Early-access deals around mechanistic novelty like this routinely price at low single-digit upfronts — a cost-effective entry point for acquirers building nucleic acid platform depth.

May 22, 2026 — FDA Grants Accelerated Approval to Gilead's Hepcludex — First U.S.-Approved Treatment for HDV

The U.S. FDA granted accelerated approval to Gilead Sciences' Hepcludex (bulevirtide-gmod) for adult patients with chronic hepatitis delta virus (HDV) infection with or without compensated cirrhosis — making Hepcludex the first and only approved treatment for HDV in the United States. HDV co-infection drives rapid liver fibrosis, cirrhosis, and elevated hepatocellular carcinoma risk. The U.S. path was protracted: the FDA issued a Complete Response Letter (CRL) in 2022 citing chemistry, manufacturing and control (CMC) deficiencies, a setback that deferred a €300M contingent milestone payment to former MYR GmbH shareholders and required years of Gilead manufacturing remediation before resubmission.

BD Implication: First-and-only status in an orphan indication (HDV affects ~5% of the 257M chronic HBV population) is a high-value commercial anchor. Companies with complementary HBV curative mechanisms — nucleoside analogues, capsid inhibitors, siRNA — should actively pursue Hepcludex combination-therapy partnership conversations with Gilead.

May 22, 2026 — FDA Approves Datroway (Dato-DXd) as First-Line Therapy for PD-L1-Ineligible TNBC

Daiichi Sankyo and AstraZeneca announced FDA approval of Datroway (datopotamab deruxtecan, Dato-DXd) as first-line therapy for adults with unresectable or metastatic triple-negative breast cancer (TNBC) who are ineligible for PD-1/PD-L1 inhibitors. Based on the TROPION-Breast02 trial, Datroway is the first treatment to demonstrate statistically significant overall survival benefit in this population: mOS 23.7 months vs. 18.7 months for chemotherapy, with an ORR of 64% vs. 30%. This is Datroway's third label expansion following prior approvals for HR+/HER2− breast cancer and NSCLC, establishing Dato-DXd as one of the broadest-indication ADCs in oncology.

BD Implication: The multi-indication trajectory of Dato-DXd confirms that TROP2 ADC platforms generate compounding commercial and strategic value across tumor types. Companies with TROP2-combination assets (TROP2 ADC + PARP inhibitor, TROP2 + IO) will attract active partnership interest from both Daiichi Sankyo/AZ and Gilead (via Trodelvy).